BioTec Announces Tens of Millions RMB Pre-A Financing to Accelerate Development of TNBC-Specific Conjugated Peptide Vaccine

Recently, Biotech & Biomedicine (Shenyang) Group Ltd. (“Biotech & Biomedicine”) announced the successful completion of its Pre-A financing round, amounting to tens of millions of RMB, exclusively invested by Liaoning Jingci Medical Investment Management Co., Ltd. (“Jingci Medical”). This milestone financing has injected strong momentum into the rapid development of the company’s product pipeline for “specific conjugated peptide vaccines.”

The proceeds from this funding round will be primarily used to accelerate the Investigational New Drug (IND) application process for BPV-01, a "triple-negative breast cancer-specific conjugated peptide vaccine" independently developed by Biotech & Biomedicine (Shenyang) Group Ltd., as well as to advance other product pipelines in development. As a peptide vaccine specifically targeting triple-negative breast cancer (TNBC), BPV-01 is distinguished by its use of highly immunogenic peptide fragments conjugated with breast cancer cell-specific surface molecules to form "conjugated peptides." This mechanism enables precise targeting of immune cells to cancer cells, thereby effectively reducing immune escape by cancer cells.

This peptide vaccine functions by binding to cancer cells and activating the immune system to generate immunological memory against these highly immunogenic peptide fragments, thereby establishing durable immunity. Upon tumor recurrence, the immune system can rapidly recognize and identify tumor cells as harmful non-self entities, enabling precise cytotoxicity. This innovative mechanism not only addresses post-treatment recurrence but also effectively prevents de novo metastasis following second-line therapy in patients with advanced-stage cancer, thereby delaying disease progression, prolonging survival, and significantly improving patients’ quality of life.

The success of this financing round not only demonstrates investors’ high recognition of Biotech & Biomedicine (Shenyang) Group Ltd.’s innovative capabilities and market potential in the field of peptide vaccines, but also further strengthens the company’s confidence in its future development. Looking ahead, the company will continue to uphold a research and development ethos centered on innovation, pragmatism, and efficiency, while actively seeking collaborations with more visionary and well-capitalized investment institutions. Together, they will accelerate the company’s rapid growth in the field of specific conjugate peptide vaccines, bringing greater benefits to patients worldwide.

Professor Ma Shiliang, Chief Scientist of Biotech & Biomedicine (Shenyang) Group Ltd.stated: “We sincerely appreciate Jingci Medical’s support and recognition of our company. This round of financing will facilitate the Investigational New Drug (IND) application and clinical translation of our specifically conjugated polypeptide vaccine product, BPV-01, as well as accelerate the development of our other pipeline candidates. We possess innovative and unique technological advantages in therapeutic vaccine drugs, and we are confident that this project will achieve success in both clinical trials and commercialization, thereby bringing more treatment opportunities to patients worldwide.”

Professor Li Jianyi, Chief Medical Officer of Biotech & Biomedicine (Shenyang) Group Ltd.It stated: “Target identification in triple-negative breast cancer (TNBC) is challenging, with primary resistance commonly observed. After first-line chemotherapy fails, second- and third-line chemotherapeutic agents generally show limited efficacy against TNBC, and there is a lack of effective therapeutic options once the disease progresses to stage IV. The peptide-conjugate vaccine developed in this project offers an innovative treatment option, holding promise for further extending patient survival. Under the leadership of a highly executable core team, rapid clinical validation is expected.”

Zhang Mi, Chairman of Jingci Medicalstated, “It is a great honor to accompany the development of Biotech & Biomedicine (Shenyang) Group Ltd. Jingci Medical focuses on growth-stage investments in the healthcare sector, with particular attention to growth-stage and early-stage investment opportunities in biomedicine and life sciences. We hope that through our joint efforts, we can promote the widespread clinical application and adoption of peptide vaccines, and we look forward to the product’s early market launch, so that these innovative achievements can benefit more patients.”

Biotech & Biomedicine (Shenyang) Group Ltd., established in 2016, is a national high-tech enterprise in China dedicated to the research and development (R&D) and industrial translation of new technologies, novel drugs, and innovative products in the life sciences sector. Its business portfolio encompasses the R&D and translation of cell engineering technologies, human microecology technologies, tumor peptide vaccines, regenerative medicine and wellness solutions, as well as the industrial translation of related life science technologies. The group is committed to building an integrated industry chain that unifies academia, research, production, and application, thereby fostering new quality productive forces.The group operates a diverse array of R&D and translation platforms, including the Biotech International Life Science Industry Complex, provincial and municipal-level new-type R&D institutions, the Liaoning Provincial Engineering Research Center for Cell Drugs and Organ Drugs, the Liaoning Provincial Professional Technology Innovation Center for Genetic Engineering, the Liaoning Provincial Comprehensive Cell Resource Bank, the Northern Microbiome Bank, and pilot-scale bases for the translation of life science achievements. These platforms enable a one-stop closed-loop process from R&D to product commercialization, establishing a mature ecosystem covering the entire life sciences industry chain.

Liaoning Jingci Medical Investment Management Co., Ltd. is a comprehensive, empowerment-focused investment firm deeply rooted in the healthcare sector, with a particular focus on growth-stage and early-stage investment opportunities in biomedicine and life sciences. Leveraging profound professional expertise and a forward-looking investment perspective, the company not only provides capital to its portfolio companies but also strives to serve as a steadfast partner in their growth journey. Jingci Medical firmly believes that true value creation stems from deep empowerment and long-term companionship for invested enterprises. By offering customized strategic planning, refined corporate management consulting, and efficient capital operation strategies, the company comprehensively empowers its portfolio companies to overcome development bottlenecks and achieve rapid growth.